TEK2day FINANCE Open Terminal →

Dr. Reddy's Laboratories Ltd (RDY)

NYQ · Healthcare · Drug Manufacturers - Specialty & Generic

$13.30 -0.45%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History -17.2% over period
$16$15$14$13$12 2025-062025-092025-122026-032026-06

Key Metrics

Market Cap
$11.40B
P/S (TTM)
0.0x
P/E (TTM)
0.3x
Exchange
NYQ

About Dr. Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Quarterly Financials

Metric2025-06-302025-09-302025-12-312026-03-31
Revenue85.5B88.1B87.3B75.2B
Gross Profit48.6B48.1B46.8B43.0B
Operating Income16.8B17.9B14.3B829.0M
Net Income14.2B14.4B12.1B2.2B
Diluted EPS$17.02$17.25$14.52$2.65

Annual Financials

Metric2023-03-312024-03-312025-03-312026-03-31
Revenue245.9B279.2B325.5B335.9B
Gross Profit139.3B163.6B225.7B213.5B
Operating Income59.1B65.3B70.1B47.5B
Net Income45.1B55.7B56.6B42.0B
Diluted EPS$54.17$66.92$67.79$50.35
Want live quotes, estimates, SEC filings, and CEO analytics for RDY?
The free TEK2day terminal runs in your browser — type /RDY to get started.
Open RDY in the Terminal →